BioSpace News Archive

The Barer Institute, a cancer drug development initiative of Rafael Holdings, Inc. , (NYSE: RFL), today announced that it has reached an agreement with Princeton University’s Office of Technology Licensing for technology from the laboratory of Professor Joshua Rabinowitz , in the Department of Chemistry, Princeton University ,

Nektar Therapeutics (NASDAQ: NKTR) today announced that it agreed to sell to entities managed by Healthcare Royalty Management, LLC (HCR) its royalties on future sales of ADYNOVATE, under Nektar’s agreement with Baxalta Incorporated, a Takeda company, and MOVANTIK, under Nektar’s agreement with AstraZeneca AB. Under the terms of th

Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has initiated the pivotal efficacy study for tirnovetmab (KIND-016), a fully caninized, high-affinity monoclonal antibody targeting interleukin (IL)-31 for the treatment of atopic dermatitis in dogs.

Neogen Corporation announced that revenues for the second quarter of its 2021 fiscal year, which ended Nov. 30, were $115,000,000, a 7% increase compared to the previous year’s second quarter revenues of $107,803,000.

The development and authorization of a COVID-19 vaccine is a critical scientific milestone in our efforts to combat this pandemic. Abbott released findings from a survey conducted by The Harris Poll, showing that Americans see testing as an essential partner to these new vaccines.

Application is for Patients With Previously Treated Non-Small Cell Lung Cancer (NSCLC) With the KRAS G12C Mutation EU Application Follows Sotorasib New Drug Application Submission to U.S. FDA Announced Last Week

Qualigen Therapeutics, Inc. (Nasdaq: QLGN) , a biotechnology company focused on developing novel therapeutics for the treatment of cancer and infectious diseases, announces that Michael Poirier , Chairman, Chief Executive Officer and President, has issued a letter to Qualigen’s stockholders. The full text is as follows: To

Rapid Medical , a company focused on the development of the first class of responsive, adjustable neurovascular devices, announces the FDA clearance of DRIVEWIRE, a novel guidewire with a steerable distal tip that handles complex anatomical turns with ease. This device is named Columbus outside of the United S

Atriomx Health, a Menlo Park, California -based developer of novel, non-invasive solutions for the detection and characterization of the underlying disease mechanisms of atrial fibrillation and other arrhythmias, announced today that it has secured a $10 million Series A financing. Ajax Health and Zeus Health will co-lead t

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the submission of the supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for DEXTENZA® (dexamethasone ophthalmic ins